… Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Applicability … J Boudet et al. A robust computational approach is developed to screen for compatible interactions between …
… which we process data We collect information in order to optimize our services offered to you and we do it in a manner … so we can address your inquiries with us, we have provided options and contact details that enable you to contact us. … receive our letters. Each mailing contains the option to opt-out. As soon as you opt-out, your name and e-mail address …
… had an incurable rare disease, he founded ProQR to help people like his son. Learn more. A personal mission A … Daniel sought help from experts in the field of drug development and formed ProQR to help people like his son. … people living with rare diseases who have no treatment options. Henri Termeer To learn more about Henri, visit the …
… company was founded in 2012, our mission has been to help people living with rare diseases that currently have no treatment options. This remains an important focus of our company … Read more about our Founding story . Patient-focused drug development Patient-focused drug development In order to …
… pdf , 1.54 Mo Download link RNA Editing Summit (2024) Developing Axiomer RNA Editing Technology Towards Clinical Development pdf , 2.83 Mo Lien externe ASGCT (2024) … to Address Liver Originated Disorders Internal link OPT Congress (2023) Gerard Platenburg, Therapeutic potential …
… ways, including via the Whistleblower Hotline which is operated by a third party SpeakUp and always available. The … confidential communication, and also allows for (optional) anonymous reporting. Report submitted to the … who will decide on further steps of investigation, as appropriate. Whistleblower Hotline reports may be made via …
… was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Before founding … background in RNA modulation and orphan drug discovery and development and is currently in charge of our R&D. Gerard has … has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
At ProQR, we are dedicated to improving the lives of patients and families affected by rare and common disorders using Axiomer, our innovative RNA editing platform technology.
